UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients

The U.K’s National Institute for Health and Care Excellence (NICE) on Wednesday recommended Pfizer Inc’s (NYSE:PFE) Adcetris (brentuximab vedotin) for adult patients with advanced Hodgkin lymphoma.

The recommendation covers brentuximab vedotin in combination with other therapies for routine National Health Service (NHS) use.

Around 800 people annually with previously untreated stage 3 or 4 CD30-positive Hodgkin lymphoma could benefit from this treatment, which combines brentuximab vedotin with doxorubicin, dacarbazine, and vinblastine.

Also Read: Pfizer Shares Are Down Today: What’s Going On?

NICE says this marks the first ...

https://www.benzinga.com/general/biotech/25/04/44614171/uks-health-agency-endorses-pfizers-blood-cancer-combo-therapy-as-first-for-untreated-hodgkin-lymp